Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …

Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …

Mutations in the germline generates all evolutionary genetic variation and is a cause of
genetic disease. Parental age is the primary determinant of the number of new germline …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from
spontaneous regression to fatal disease. When these different tumors originate and how …

Multiple myeloma (MM) is consistently preceded by precursor conditions recognized
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking
immunotherapies approved for use against large B-cell lymphomas. Although host …